Attention: You are using an outdated browser, device or you do not have the latest version of JavaScript downloaded and so this website may not work as expected. Please download the latest software or switch device to avoid further issues.

News > Community news > Crick spinout to begin first-in-human clinical study for leukaemia

Crick spinout to begin first-in-human clinical study for leukaemia

GammaDelta Therapeutics has received Investigational New Drug approval from the US FDA for their GDX012 cell therapy to be investigated as a treatment for blood cancers. 
7 Jun 2021
United States of America
Community news



To view this News Article

Similar stories

Crick postdoc Catherine Hurd has been awarded a Wellcome Trust Early Career Award. She tells us about her research at the Crick, plans for the future, and how the Postdoc to PI pro… More...

Pontus Skoglund, Group Leader of the Crick Ancient Genomics Laboratory, has been awarded a €2m Consolidator Grant from t… More...

Huge congratulations to Principal Group Leader - Assistant Research Director Caroline Hill and Seconded Group Leader Xia… More...

Congratulations to Crick Group Leader Pontus Skoglund has been awarded the 2023/24 Balfour Lecture by The Genetics Socie… More...

Have your say


Contact us

The Francis Crick Institute
1 Midland Road

This website is powered by